Novartis has admitted and accepted responsibility for many of the allegations and agreed to scale back its speaker programs.
As part of the settlement, Novartis has entered into a “corporate integrity agreement” with the inspector general at the US Department of Health and Human Services.
The five-year agreement requires Novartis to significantly curtail its paid speaker programme, restricting any events to virtual format only.
Vas Narasimhan, Novartis chief executive, said “Today’s settlements are consistent with Novartis commitment to resolve and learn from legacy compliance matters.”
